Bristol-Myers Wants Fed. Circ.'s En Banc Review Of Patent
Bristol-Myers Squibb Co. on Monday pressed the Federal Circuit for another chance to show its patent for hepatitis B drug Baraclude was valid, arguing that the court's decision affirming the patent...To view the full article, register now.
Already a subscriber? Click here to view full article